{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:56:49Z","timestamp":1792112209868,"version":"4.4.0"},"reference-count":98,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Age\u2010related macular degeneration is a global disease with a significant societal impact. The advent of anti\u2010vascular endothelial growth factor therapy (anti\u2010VEGF) has revolutionised the treatment of neovascular age\u2010related macular degeneration (nAMD). Dry age\u2010related macular degeneration (dAMD) is being investigated for possible therapeutic options. The therapeutic categories undergoing clinical trials include complement pathway inhibitors, visual cycle modulators, reduction of toxic byproducts, antioxidative therapy, neuroprotective agents, laser therapy, surgical options, gene therapy, stem cell therapy, and miscellaneous treatments. Two intravitreal anti\u2010complement factors (pegcetacoplan and avacincaptad pegol) have recently shown phase 3 clinical trial evidence of a reduction in the growth of geographic atrophy. In this review, we provide an update on treatment options currently undergoing clinical research trials for the management of dAMD and preventing the progression of Geographic Atrophy (GA).<\/jats:p>","DOI":"10.1111\/ceo.14294","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T06:16:09Z","timestamp":1695363369000},"page":"835-852","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Treatment of dry age\u2010related macular degeneration: A review"],"prefix":"10.1111","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6023-3979","authenticated-orcid":false,"given":"Shenouda","family":"Girgis","sequence":"first","affiliation":[{"name":"City Eye Centre  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence R.","family":"Lee","sequence":"additional","affiliation":[{"name":"City Eye Centre  Brisbane Australia"},{"name":"Royal Brisbane and Women's Hospital  Brisbane Australia"},{"name":"Faculty of Medicine University of Queensland  Saint Lucia Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"e_1_2_16_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.09.028"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.036"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01765-x"},{"key":"e_1_2_16_6_1","unstructured":"Apellis Pharmaceuticals Inc.Study to Compare the Efficacy and Safety of Intravitreal APL\u20102 Therapy With Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age\u2010Related Macular Degeneration. ClinicalTrials.gov identifier: NCT03525600. Updated June 22 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03525600. Accessed November 1 2022."},{"key":"e_1_2_16_7_1","unstructured":"Apellis Pharmaceuticals Inc.A Study to Compare the Efficacy and Safety of Intravitreal APL\u20102 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age\u2010Related Macular Degeneration. ClinicalTrials.gov identifier: NCT03525613. Updated June 22 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03525613. Accessed 1 November 2022"},{"key":"e_1_2_16_8_1","unstructured":"Apellis Apellis Announces 24\u2010Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) 2022.https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-announces-24-month-results-showing-increased-effects. Accessed November 2022"},{"key":"e_1_2_16_9_1","first-page":"1500","article-title":"Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12\u2010month results from the phase 3 OAKS and DERBY studies","volume":"63","author":"Goldberg R","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_16_10_1","volume-title":"Safety of Intravitreal Pegcetacoplan in Geographic Atrophy: 24 Month Results from the OAKS and DERBY Phase 3 Trials","author":"Singh R","year":"2022"},{"key":"e_1_2_16_11_1","unstructured":"Efficacy of intravitreal pegcetacoplan in geographic atrophy: 24\u2010month results from the phase 3 OAKS and DERBY trials.https:\/\/investors.apellis.com\/static\u2010files\/78d1b209\u20107324\u20104c4c\u20108b20\u2010bf7778493bae. Accessed July 24 2023"},{"key":"e_1_2_16_12_1","unstructured":"FDA FDA drug documenters 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/217171Orig1s000ltr.pdf. Accessed April 2023"},{"key":"e_1_2_16_13_1","unstructured":"Apellis and ASRS ReST provides update on review of rare safety events with SYFOVRE\u00ae (pegcetacoplan injection) for Geographic Atrophy.https:\/\/investors.apellis.com\/news\u2010releases\/news\u2010release\u2010details\/apellis\u2010provides\u2010update\u2010review\u2010rare\u2010safety\u2010events\u2010syfovreand https:\/\/www.asrs.org\/clinical\/clinical-updates\/9327\/ASRS-Research-and-Safety-in-Therapeutics-REST-Committee-Update-on-Adverse-Events. Accessed August 2023"},{"key":"e_1_2_16_14_1","unstructured":"Apellis Pharmaceuticals Inc.An extension study to evaluate the long\u2010term safety and efficacy of pegcetacoplan (APL\u20102) in subjects with geographic atrophy secondary to AMD (GALE). ClinicalTrials.gov identifier: NCT04770545. Updated August 30 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04770545. Accessed November 1 2022"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.08.027"},{"key":"e_1_2_16_16_1","unstructured":"IVERIC BIO Announces positive Zimura 18 month data supporting the 12 month efficacy findings: continuous positive treatment effect with favorable safety profile in geographic atrophy secondary to age\u2010related macular degeneration in a phase 3 trial 2020.https:\/\/www.prnewswire.com\/news\u2010releases\/iveric\u2010bio\u2010announces\u2010positive\u2010zimura\u201018\u2010month\u2010data\u2010supportingthe\u201012\u2010month\u2010efficacy\u2010findings\u2010continuous\u2010positive\u2010treatment\u2010effect\u2010withfavorable\u2010Safety\u2010profile\u2010in\u2010geographic\u2010atrophy\u2010secondary\u2010to\u2010age\u2010related\u2010macular. Accessed November 2022"},{"key":"e_1_2_16_17_1","unstructured":"IVERIC bio Inc.A phase 3 safety and efficacy study of intravitreal administration of Zimura (complement C5 inhibitor). ClinicalTrials.gov identifier: NCT04435366. Updated September 28 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435366. Accessed November 1 2022"},{"key":"e_1_2_16_18_1","unstructured":"Iveric Bio Receives U.S.FDA Approval for IZERVAY\u2122 (avacincaptad pegol intravitreal solution) a New Treatment for Geographic Atrophy.https:\/\/www.astellas.com\/en\/news\/28281. Accessed August 2023"},{"key":"e_1_2_16_19_1","first-page":"4305","article-title":"Development of IONIS\u2010FB\u2010LRx to treat geographic atrophy associated with AMD","volume":"61","author":"Jaffe GJ","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_16_20_1","unstructured":"Ionis Pharmaceuticals Inc.A phase 2 randomized placebo\u2010controlled double\u2010masked study to assess safety and efficacy of multiple doses of IONIS\u2010FB\u2010LRx an antisense inhibitor of complement factor B in patients with geographic atrophy secondary to age\u2010related macular degeneration (AMD). ClinicalTrials.gov Identifier: NCT03815825 Updated August 22 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03815825. Accessed November 1 2022"},{"key":"e_1_2_16_21_1","first-page":"1798","article-title":"NGM621 is a potent inhibitory anti\u2010complement C3 antibody in development for treatment of geographic atrophy","volume":"61","author":"Loktev A","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.08.018"},{"key":"e_1_2_16_23_1","unstructured":"NGM Biopharmaceuticals Inc.A Phase 2 Multicenter Randomized Double\u2010Masked Sham\u2010Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age\u2010Related Macular Degeneration (AMD). ClinicalTrials.gov identifier: NCT04465955. Updated August 23 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04465955. Accessed November 1 2022."},{"key":"e_1_2_16_24_1","first-page":"219","article-title":"Pharmacokinetics and target engagement of intravitreal administration of ANX007, an anti\u2010C1q antibody fragment, in nonhuman primates","volume":"62","author":"Grover A","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_16_25_1","unstructured":"Annexon Inc.A Phase 1b Randomized Double\u2010masked Sham\u2010Controlled Study of ANX007 Administered as Intravitreal Injections to Assess Safety and Tolerability in Participants With Primary Open\u2010angle Glaucoma. ClinicalTrials.gov identifier: NCT04188015. Updated August 20 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04188015. Accessed November 1 2022"},{"key":"e_1_2_16_26_1","unstructured":"Annexon Biosciences Spotlight on ANX007\u2010Inhibition of Cq1 for GA 2021.https:\/\/annexonbio.com\/wp-content\/uploads\/2021\/10\/Dry-AMD-Therapeutic-Development_Don-Fong_2021-10-20.pdf. Accessed November 2022"},{"key":"e_1_2_16_27_1","unstructured":"Annexon Inc.A Phase 2 Multicenter Randomized Parallel\u2010Group Double\u2010Masked 4\u2010Arm Sham\u2010Controlled Study of the Efficacy Safety and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age\u2010Related Macular Degeneration (AMD)\u2014The ARCHER Study. ClinicalTrials.gov identifier: NCT04656561. Updated July 5 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04656561. Accessed November 1 2022"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820892116"},{"key":"e_1_2_16_29_1","unstructured":"Novartis Pharmaceuticals.This is a multicenter randomized participant and investigator masked placebo controlled proof\u2010of\u2010concept study to assess the safety and efficacy of LNP023 in participants with early to intermediate age\u2010related macular degeneration (e\/iAMD) in one eye and neovascular age\u2010related macular degeneration (nAMD) in the other eye. ClinicalTrials.gov identifier: NCT05230537. Updated September 22 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05230537. Accessed November 1 2022"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.153312"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261826"},{"key":"e_1_2_16_32_1","unstructured":"Alexion Pharmaceuticals.A Phase 2 Double\u2010Masked Placebo\u2010Controlled Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age\u2010Related Macular Degeneration (AMD). ClinicalTrials.gov identifier: NCT05019521. Updated October 20 2020. Accessed November 1 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05019521"},{"key":"e_1_2_16_33_1","unstructured":"RosenfelPJ.Complement Inhibition With Eculizumab for the Treatment of Non\u2010Exudative Macular Degeneration (AMD) (COMPLETE). ClinicalTrials.gov identifier: NCT00935883. Updated May 30 2017.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00935883. Accessed November 1 2022"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.044"},{"key":"e_1_2_16_35_1","unstructured":"Novartis Pharmaceuticals.A Multicenter Randomized Sham\u2010control Proof\u2010of\u2010concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age\u2010related Macular Degeneration. ClinicalTrials.gov identifier: NCT01527500. Updated January 5 2021. Accessed November 1 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01527500"},{"key":"e_1_2_16_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2021.03.016"},{"key":"e_1_2_16_37_1","unstructured":"Astellas Institute for Regenerative Medicine.A Phase I\/II Open\u2010Label Multi\u2010Center Prospective Study to Determine the Safety and Tolerability of Sub\u2010retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09\u2010hRPE) Cells in Patients With Advanced Dry AMD. ClinicalTrials.gov identifier: NCT01344993. Updated July 7 2021. Accessed November 1 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01344993"},{"key":"e_1_2_16_38_1","unstructured":"Astellas Institute for Regenerative Medicine.Long Term Follow up to A Phase I\/II Open\u2010Label Multi\u2010Center Prospective Study to Determine the Safety and Tolerability of Sub\u2010retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09\u2010hRPE) Cells in Patients With Advanced Dry AMD. ClinicalTrials.gov identifier: NCT02463344. Updated November 13 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02463344. Accessed November 1 2022"},{"key":"e_1_2_16_39_1","unstructured":"Initiatives in Cell Therapy.Turning Innovative Science into value for patients 2018.https:\/\/www.astellas.com\/en\/system\/files\/final_2_181212_rd_day_eg.pdf. Accessed November 2022"},{"key":"e_1_2_16_40_1","unstructured":"LebkowskiJ.A Phase I\/IIa Safety Study of Subretinal Implantation of CPCB\u2010RPE1 (Human Embryonic Stem Cell\u2010Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced Dry Age\u2010Related Macular Degeneration (AMD). ClinicalTrials.gov identifier: NCT02590692. Updated May 29 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02590692. Accessed November 1 2022"},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.10.13"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2022.01.001"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szac001"},{"key":"e_1_2_16_44_1","unstructured":"CostaMT.A Phase I\/IIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell\u2010Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age\u2010Related Macular Degeneration. ClinicalTrials.gov identifier: NCT04339764. Updated August 16 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04339764. Accessed November 1 2022"},{"key":"e_1_2_16_45_1","unstructured":"Astellas Institute for Regenerative Medicine.A Phase 1b Multicenter Dose Escalation Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age\u2010related Macular Degeneration. ClinicalTrials.gov identifier: NCT03178149. Updated September 26 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03178149. Accessed November 1 2022"},{"key":"e_1_2_16_46_1","unstructured":"WeissJ.Bone marrow derived stem cell ophthalmology treatment study II. ClinicalTrials.gov identifier: NCT03011541. Updated August 3 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03011541. Accessed November 1 2022"},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2008-0836"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15069372"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicines7040016"},{"key":"e_1_2_16_50_1","article-title":"Key takeaways from the RGX\u2010314 phase I\/IIa clinical trial for wet AMD (cohorts 1\u20105)","author":"Heier J","year":"2019","journal-title":"Am Acad Ophthalmol"},{"key":"e_1_2_16_51_1","first-page":"2295","article-title":"GT005, a gene therapy for the treatment of dry age\u2010related macular degeneration (AMD)","volume":"61","author":"Ellis S","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_16_52_1","unstructured":"Gyroscope Therapeutics Limited.A dose escalation study of the safety and efficacy of a single subretinal injection of GT005 in subjects with Macular Atrophy due to AMD. ClinicalTrials.gov identifier: NCT03846193. Updated October 13 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03846193. Accessed November 1 2022"},{"key":"e_1_2_16_53_1","unstructured":"Gyroscope Therapeutics Limited.This is a Phase II open\u2010label outcomes\u2010assessor masked multicentre randomised controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD. ClinicalTrials.gov identifier: NCT04566445. Updated August 2 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04566445. Accessed November 1 2022"},{"key":"e_1_2_16_54_1","unstructured":"Gyroscope Therapeutics Limited.EXPLORE: A Phase II Outcomes Assessor\u2010masked Multicentre Randomised Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age\u2010related Macular Degeneration. ClinicalTrials.gov identifier: NCT04437368. Updated December 2 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04437368. Accessed November 1 2022"},{"key":"e_1_2_16_55_1","unstructured":"HeierJ.A Phase 1 Open\u2010Label Multi\u2010Center Dose\u2010Escalating Safety and Tolerability Study of a Single Intravitreal Injection of AAVCAGsCD59 in Patients With Advanced Non\u2010Exudative (Dry) Age\u2010Related Macular Degeneration With Geographic Atrophy. ClinicalTrials.gov identifier: NCT04437368. Updated April 2 2021. Accessed November 1 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03144999"},{"key":"e_1_2_16_56_1","unstructured":"Hemera Biosciences.A Phase 2 Multi\u2010Center Trial Evaluating Intravitreal AAVCAGsCD59 Compared to Sham Injection for the Treatment of Advanced Dry Age\u2010Related Macular Degeneration (AMD) With Geographic Atrophy (GA).ClinicalTrials.govidentifier: NCT04358471. Updated May 10 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04358471. Accessed November 1 2022"},{"key":"e_1_2_16_57_1","unstructured":"Janssen Pharmaceuticals 2022.https:\/\/eyewire.news\/articles\/janssen-acquires-rights-to-hemera-biosciences-investigational-gene-therapy-for-late-stage-amd\/?c4src=article:infinite-scroll. Accessed November 2022."},{"key":"e_1_2_16_58_1","unstructured":"GuymerRH.A Multi\u2010centre Randomized Trial Into the Safety and Efficacy of Nanosecond Microsurgical Laser Intervention in Early Age\u2010related Macular Degeneration. ClinicalTrials.gov identifier: NCT01790802. Updated July 6 2018.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01790802. Accessed November 1 2022"},{"key":"e_1_2_16_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.09.015"},{"key":"e_1_2_16_60_1","unstructured":"GuymerRH.Subthreshold Laser Treatment in Intermediate Age\u2010related Macular Degeneration With Nascent Geographic Atrophy Study. ClinicalTrials.gov identifier: NCT05200624. Updated January 21 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05200624. Accessed November 1 2022."},{"key":"e_1_2_16_61_1","unstructured":"QuerquesG SacconiR GelorminiF.Subthreshold Laser Treatment for Reticular Pseudodrusen and Incipient Geographic Atrophy Secondary to Age\u2014Related Macular Degeneration: a Pilot Study. ClinicalTrials.gov identifier: NCT02800356. Updated February 17 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02800356. Accessed November 1 2022"},{"key":"e_1_2_16_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81810-7"},{"key":"e_1_2_16_63_1","unstructured":"Evaluation of the R: GEN Laser System as an Intervention in Subjects with Early Stages of Age\u2010related Macular Degeneration (AMD) for Safety and Exploratory Efficacy Outcomes (LASER LIGHT\u201001).https:\/\/www.cera.org.au\/trials\/evaluation\u2010of\u2010the\u2010rgen\u2010laser\u2010system\u2010as\u2010an\u2010intervention\u2010in\u2010subjects\u2010with\u2010early\u2010stages\u2010of\u2010age\u2010related\u2010macular\u2010degeneration\u2010amd\u2010for\u2010safety\u2010and\u2010exploratory\u2010efficacy\u2010outcomes\u2010laser\u2010light\u201001\/. Accessed March 21 2023"},{"key":"e_1_2_16_64_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S272327"},{"key":"e_1_2_16_65_1","first-page":"2049","article-title":"Photobiomodulation as a new treatment for dry age related macular degeneration RESULTS from the Toronto and oak ridge photobimodulation study in AMD (TORPA)","volume":"53","author":"Merry G","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_16_66_1","unstructured":"LumiThera Inc.Study of photobiomodulation to treat non\u2010exudative age\u2010related macular degeneration (LIGHTSITE II). ClinicalTrials.gov Identifier: NCT03878420; 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03878420. Accessed July 19 2020"},{"key":"e_1_2_16_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13354"},{"key":"e_1_2_16_68_1","unstructured":"LIGHTSITE III trial data demonstrates improvement in vision in intermediate dry AMD.https:\/\/www.ophthalmologytimes.com\/view\/lightsite-iii-trial-data-demonstrates-improvement-in-vision-in-intermediate-dry-amd. Accessed March 21 2023"},{"key":"e_1_2_16_69_1","unstructured":"Allegro OphthalmicsLLC.A Randomized Controlled Double\u2010Masked Crossover Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate\u00ae (Alg\u20101001) As A Treatment For Non\u2010Exudative Macular Degeneration. ClinicalTrials.gov identifier: NCT03626636. Updated July 8 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03626636. Accessed November 1 2022"},{"key":"e_1_2_16_70_1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20220725-02"},{"key":"e_1_2_16_71_1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20210528-05"},{"key":"e_1_2_16_72_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.178657"},{"key":"e_1_2_16_73_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.178640"},{"key":"e_1_2_16_74_1","unstructured":"SchollH SaadL.A Phase 2 Multicenter Double\u2010Masked Randomized Placebo\u2010Controlled Study to Investigate the Long Term Safety Tolerability Pharmacokinetics and Effects of ALK\u2010001 on the Progression of Stargardt Disease.ClinicalTrials.govidentifier: NCT02402660. Updated March 3 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT0240266077. Accessed November 1 2022"},{"key":"e_1_2_16_75_1","first-page":"38","article-title":"ALK\u2010001 (C20\u2010D3\u2010vitamin a) slows the growth of atrophic lesions in ABCA4\u2010related Stargardt disease: results of a phase 2 placebo\u2010controlled clinical trial (TEASE study)","volume":"63","author":"Scholl HP","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_16_76_1","unstructured":"SaadL.A Phase 2\/3 Multicenter Randomized Double\u2010masked Parallel\u2010group Placebo\u2010controlled Study to Investigate the Safety Pharmacokinetics Tolerability and Efficacy of ALK\u2010001 in Geographic Atrophy Secondary to Age\u2010related Macular Degeneration. ClinicalTrials.gov identifier: NCT03845582. Updated February 16 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03845582. Accessed November 1 2022"},{"key":"e_1_2_16_77_1","first-page":"2126","article-title":"Mitochondrial dysfunction in experimental mouse models of SubRPE deposit formation and reversal by the Mito\u2010reparative drug MTP\u2010131","volume":"57","author":"Cousins SW","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_16_78_1","unstructured":"CousinsSW.An Open\u2010Label Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age\u2010Related Macular Degeneration. ClinicalTrials.gov identifier: NCT02848313. Updated October 20 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02848313. Accessed November 1 2022"},{"key":"e_1_2_16_79_1","unstructured":"Stealth BioTherapeutics.Stealth biotherapeutics announces positive results for elamipretide in ophthalmic conditions 2019.https:\/\/www.prnewswire.com\/news\u2010releases\/stealth\u2010biotherapeutics\u2010announces\u2010positive\u2010results\u2010for\u2010elamipretide\u2010in\u2010ophthalmic\u2010conditions\u2010300841246.html. Accessed November 2022"},{"key":"e_1_2_16_80_1","unstructured":"Stealth BioTherapeutics Inc.A Phase 2 Randomized Double\u2010Masked Placebo\u2010Controlled Clinical Study to Evaluate the Safety Efficacy and Pharmacokinetics of Elamipretide in Subjects With Age\u2010Related Macular Degeneration With Non\u2010central Geographic Atrophy. ClinicalTrials.gov identifier: NCT03891875. Updated May 26 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03891875. Accessed November 1 2022"},{"key":"e_1_2_16_81_1","first-page":"2625","article-title":"Topical administration of MRZ\u201099030, a\u2010amyloid aggregation modulator, protects retinal ganglion cells and axons in a rodent model of glaucoma","volume":"54","author":"Gravius A","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_16_82_1","first-page":"5393","article-title":"Sustained neuroprotective effect of novel A\u03b2 aggregation modulator GAL\u2010101 shown in dry AMD and glaucoma models with transient peak concentrations using eye drops","volume":"60","author":"Russ H","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_16_83_1","unstructured":"Merz Pharmaceuticals GmbH.Safety and tolerability of MRZ\u201099030 eye drops in healthy volunteers and glaucoma patients. ClinicalTrials.gov identifier: NCT01714960. Updated January 29 2014.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01714960. Accessed November 1 2022"},{"key":"e_1_2_16_84_1","unstructured":"Alzheon Pipeline 2022.https:\/\/alzheon.com\/pipeline\/. Accessed November 2022"},{"key":"e_1_2_16_85_1","unstructured":"Retrotope 2021.https:\/\/www.retrotope.com\/press\u2010release\/positive\u2010results\u2010from\u2010studies\u2010of\u2010retrotopes\u2010rt011\u2010in\u2010animal\u2010models\u2010of\u2010retinal\u2010degeneration\u2010to\u2010be\u2010featured\u2010in\u2010oral\u2010presentations\u2010at\u20102nd\u2010annual\u2010dry\u2010amd\u2010therapeutic\u2010development\u2010summit\/. Accessed November 2022"},{"key":"e_1_2_16_86_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.4997"},{"key":"e_1_2_16_87_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.7376"},{"key":"e_1_2_16_88_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.2009.27594"},{"key":"e_1_2_16_89_1","unstructured":"Evergreen Therapeutics Inc.A Phase 2 Parallel Randomized Open\u2010label Controlled Study of EG\u2010301 150 mg Daily in Patients With Nonfocal Geographic Atrophy Secondary to dAMD. ClinicalTrials.gov identifier: NCT05170048. Updated July 29 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05170048. Accessed November 1 2022"},{"key":"e_1_2_16_90_1","unstructured":"Pixium VisionSA.Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration. ClinicalTrials.gov identifier: NCT03333954. Updated March 10 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03333954. Accessed November 1 2022"},{"key":"e_1_2_16_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.02.024"},{"key":"e_1_2_16_92_1","unstructured":"Pixium VisionSA.Restoration of Central Vision With the PRIMA System in Patients With Atrophic Age\u2010Related Macular Degeneration. ClinicalTrials.gov identifier: NCT05170048. Updated July 29 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04676854. Accessed November 1 2022"},{"key":"e_1_2_16_93_1","unstructured":"MartelJ.Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration. ClinicalTrials.gov identifier: NCT03392324. Updated June 7 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03392324. Accessed November 1 2022"},{"key":"e_1_2_16_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.07.010"},{"key":"e_1_2_16_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.05.017"},{"key":"e_1_2_16_96_1","unstructured":"McKeeHJ.A Prospective Multicenter Clinical Study of the Implantable Miniature Telescope Model SING in Patients With Central Vision Impairment Associated With End\u2010stage Age\u2010related Macular Degeneration (AMD). ClinicalTrials.gov identifier: NCT05438732. Updated August 24 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05438732. Accessed November 1 2022"},{"key":"e_1_2_16_97_1","unstructured":"WilburLR.A Clinical Study to Evaluate the Safety and Feasibility of the OcuDyne System in the Treatment of Age\u2010Related Macular Degeneration (AMD).ClinicalTrials.govidentifier: NCT05091476. Updated August 9 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05091476. Accessed November 1 2022"},{"key":"e_1_2_16_98_1","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2021-018222"},{"key":"e_1_2_16_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.08.003"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.14294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T03:01:00Z","timestamp":1699844460000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ceo.14294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":98,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/ceo.14294"],"URL":"https:\/\/doi.org\/10.1111\/ceo.14294","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"2022-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}